International Journal of Clinical Oncology and Cancer Research
2026, Vol. 11, No. 2, pp. 43–47
https://doi.org/10.11648/j.ijcocr.20261102.12

SciencePG
Science Publishing Group

Research Article

Proteomics in Cancer Detection and Treatment: Biomarker Discovery and Personalized Medicine

Muhammad Ahsan*

Department of Biotechnology, Pak-Austria University, Haripur, Pakistan

Abstract

Proteomics has emerged as a transformative field in cancer research by providing comprehensive insights into protein expression, structure, function, interactions, and post-translational modifications associated with tumor development and progression. Cancer is a complex and heterogeneous disease influenced by genetic, molecular, cellular, tissue, environmental, and socioeconomic factors that continuously evolve throughout disease progression. Despite remarkable advances in cancer diagnosis and treatment, the disease remains one of the leading causes of mortality worldwide, highlighting the need for more accurate diagnostic biomarkers and personalized therapeutic approaches. This review aims to examine the role of proteomics in cancer biomarker discovery and its contribution to the development of personalized medicine for cancer detection and treatment. The review is based on published literature describing recent advances in proteomic technologies, cancer biomarker identification, proteogenomics, and precision oncology. Current evidence demonstrates that proteomics has significantly improved the identification of reliable biomarkers for early cancer detection, tumor classification, prognosis, therapeutic target discovery, and treatment monitoring. Furthermore, integration of proteomics with genomic data has enhanced understanding of cancer progression and individualized therapy. Overall, proteomics represents a powerful platform for advancing cancer diagnosis, biomarker discovery, and personalized medicine.

Keywords

Proteomics, Cancer, Cancer Biomarkers, Personalized Medicine, Precision Oncology, Proteogenomics, Post-Translational Modifications, Single-Cell Proteomics

1. Introduction

Cancer is a complex, heterogeneous disease modulated by a wide spectrum of factors, such as genetic, molecular, cellular, tissue, population, environmental and socioeconomic factors, which evolve with time. Cancer was responsible for almost 10 million deaths in 2020 [1, 2], making it the second most common cause of death worldwide. Currently 9/10 of the top pharma companies have a focus on cancer therapeutics, breast cancer (BC) being the leading target.

Whilst there has been success in reducing mortality in some cancers [2], the updated Globocan 2020 report released by the International Agency for Research on Cancer (IARC) indicates that the global cancer burden has risen to 19.3 million cases and is predicted to rise to 30.3 million cases by 2040. Faced with this multifaceted global health issue, many research efforts have focused on the underlying disease biology and the development of innovative new treatments.

*Correspondence: Muhammad Ahsan (Ahsan.muhammad12.g@gmail.com)

Received: 20 June 2026; **Accepted:** 2 July 2026; **Published:** 24 July 2026

Whilst the traditional “one-size-fits-all” non-precision approach to patient care using surgery, chemotherapy, radiotherapy and immunotherapy has achieved some therapeutic efficacy, many problems still have to be overcome, including recurrence [3], often associated with drug resistance [4], which facilitates tumor metastasis [5, 6] and eventually promotes cancer progression [7].

And in this context proteomics plays a crucial role in changing this “one-size fits-all” approach by developing personalized medicine for specific individual with specific type of cancer. Proteomics is the large-scale study of proteins, particularly their structures, functions, interactions, and expression patterns within a cell, tissue, or organism under specific conditions. It aims to understand how proteins influence biological processes and disease mechanisms [8].

Proteomics leads to discovery of cancer biomarkers (biomarker may be defined as a specific characteristic that can be measured as an indicator of normal biological processes, pathogenic processes or responses to an exposure or intervention [10] that are used to indicate the location and type of cancer and by using these cancer biomarkers proteomics also leads to development of specific personalized medicine against that type of cancer.

2. Literature Review

Cancer remains one of the most serious global health challenges, affecting millions of people every year and contributing significantly to worldwide mortality rates [1, 2]. Despite remarkable advances in chemotherapy, targeted therapies, and immunotherapy, many cancers eventually develop resistance to treatment. In some cases, therapeutic interventions may even contribute to disease progression or metastatic spread [4, 5]. These ongoing challenges have encouraged researchers to look beyond genomic information and focus on proteomics, the large-scale study of proteins, which provides a more direct understanding of the biological processes occurring within cancer cells [8].

The field of cancer proteomics began to gain momentum when Aebersold and Mann highlighted the potential of mass spectrometry-based technologies for analyzing entire protein networks within biological systems [8]. Their work established proteomics as a powerful tool for investigating disease mechanisms at the molecular level. Around the same time, Veenstra emphasized the importance of proteins in cancer biomarker discovery, noting that proteins are not only responsible for carrying out most cellular functions but are also the primary targets of many therapeutic drugs [9].

Unlike the genome, which remains relatively stable throughout an individual's life, the proteome is highly dynamic and constantly changes in response to disease progression, environmental factors, and treatment pressures. Because of this, proteins often provide a more accurate representation of a tumor's current biological state than genetic information alone [8, 9]. Califf further stressed that biomarkers intended for clinical use must undergo rigorous validation and standardization before they can reliably guide patient care, a principle that continues to shape translational proteomics research today [10].

A major breakthrough in the field came from the proteogenomic study conducted by Mertins and colleagues, who integrated genomic, proteomic, and phosphoproteomic data to investigate breast cancer [11]. Their work demonstrated how genetic mutations influence protein signaling pathways within tumors, revealing the functional consequences of genomic alterations. This study highlighted an important concept in precision oncology: identifying a mutation is only the first step. Proteomics helps determine whether that mutation is biologically active, whether it affects key signaling pathways, and whether it can be effectively targeted with specific therapies. Such information is essential for developing truly personalized treatment strategies [11].

Recent advances have pushed proteomics even further through the development of single-cell proteomic technologies [14]. These emerging approaches allow researchers to analyze proteins within individual cells, uncovering the extensive heterogeneity that exists within tumors [12]. This is particularly important because small populations of therapy-resistant cells often survive treatment and eventually drive disease recurrence and metastasis.

By identifying these aggressive cell populations at an early stage, single-cell proteomics may provide new opportunities for improving treatment outcomes [13]. The growing importance of proteomics in oncology has led many researchers to view it as a cornerstone of personalized medicine. Su and colleagues emphasized that proteomic profiling enables clinicians to classify tumors based on their actual protein expression patterns rather than relying solely on genetic mutations or traditional pathological assessments [13]. This approach allows treatments to be tailored more precisely to the molecular characteristics of each patient's disease.

Beyond diagnosis, proteomics is increasingly influencing therapeutic decision-making. Comprehensive protein profiling can identify dysregulated signaling pathways, reveal potential drug targets, and predict patient responses to specific treatments. As a result, clinicians may be able to select therapies with greater accuracy while avoiding ineffective treatments that expose patients to unnecessary toxicity. In this way, proteomics is evolving from a biomarker discovery platform into a valuable tool for guiding cancer treatment and monitoring therapeutic response.

Looking toward the future, advances in artificial intelligence, high-resolution mass spectrometry, and large-scale collaborative research initiatives are expected to further accelerate progress in cancer proteomics. The ultimate goal is to incorporate proteomic profiling into routine clinical practice, enabling continuous monitoring of disease progression, treatment response, and early signs of relapse. However, several important challenges must still be addressed before this vision can be fully realized.

2.1. Cancer Proteogenomics: Highlighting Use of Proteomics Along with Genomics for Personalized Cancer Drugs Development

Cancer proteogenomic is the powerful approach that combines the genomics and proteomics together for the detection of cancer and development of personalized drug against it. Genomics (study of genome) shows the mutations that took place in an organism while proteomics (study of protein structure function and interaction) describes that how mutation transform a normally functioning protein into a cancerous protein either by its interaction with abnormal protein or protein conversion into cancerous protein by post-translational modifications such as methylation, lapidating or poly-acetylation etc. Proteomics fills the gap between the mutations identified by the application of genomic and protein conversion to cancerous proteins.

For instance, in breast cancer research by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), proteogenomics analysis revealed distinct protein expression patterns in basal-like tumors that were not evident through genomics alone. This led to the identification of new drug targets and helped stratify patients more accurately for treatments such as AKT inhibitors. Similarly, in lung and ovarian cancers, integrating proteomic data with genomic sequencing has exposed mechanisms of drug resistance and uncovered potential biomarkers for treatment response [11].

These findings highlight the value of proteogenomics in tailoring cancer therapies to individual patients, ultimately advancing the development of precision oncology [16].

2.2. Challenges in Clinical Translation of Cancer Proteomics

2.2.1. Analytical Complexity and Reproducibility

Proteomic studies generate vast amounts of complex data, making analysis and interpretation challenging. Differences in sample preparation methods, instrument performance, and computational workflows can result in variability between studies, limiting reproducibility and confidence in findings [11-13]. Establishing standardized protocols and quality control measures is therefore essential for ensuring reliable and comparable results across laboratories.

2.2.2. Clinical Validation and Regulatory Approval

The discovery of a potential biomarker is only the first step in a lengthy translational process. Biomarkers must be validated in large and diverse patient populations before they can be adopted in clinical practice [15]. In addition, obtaining regulatory approval often requires extensive evidence of clinical utility, making the process both time-consuming and costly [10]. Consequently, many promising proteomic biomarkers fail to reach routine clinical application.

2.2.3. Tumor Heterogeneity and Sample Collection

Cancer is a highly heterogeneous disease, with substantial variation occurring both within individual tumors and among patients [11-13]. This complexity makes it difficult to obtain representative tissue samples and accurately characterize tumor biology. Although minimally invasive approaches such as liquid biopsy show great promise, challenges related to sample quality and sensitivity remain significant barriers to widespread implementation.

2.2.4. Cost and Limited Accessibility

Advanced proteomic technologies require expensive instrumentation and highly specialized expertise. As a result, access to state-of-the-art proteomic analysis is currently limited to well-funded research institutions and specialized medical centers [12, 13]. Reducing costs and simplifying workflows will be crucial for expanding access and ensuring that proteomics can benefit patients in a broader range of healthcare settings.

2.2.5. Data Integration and Biological Interpretation

Proteomic information alone cannot provide a complete picture of cancer biology. To generate clinically meaningful insights, protein data must be integrated with genomic, transcriptomic, imaging, and clinical information [11, 13]. This requires sophisticated computational tools and strong collaboration among researchers, clinicians, and bioinformaticians. Developing effective strategies for multi-omics data integration remains one of the most important challenges in precision oncology.

2.3. Future Directions

Play a very vital role in detection of cancer in development of personalized medicine against cancer. As proteomics is continuously developing with times and let to development of new technology like single cell proteomics which deals with the proteome of single cell including its interactions with other cells, properties, characteristics, and functions of a single cell either it is natural or tumor cell [12]. This single cell proteomics plays crucial role in directing future cancer studies and development of personalized medicine against cancer. Similarly the multi-omics approaches like cancer proteogenomics also play very important role in future cancers studies because it can tell us about the whole process of cancer very easily from identifying single mutations in a cell to development of a cancerous protein.

3. Conclusion

Cancer is a complex, heterogeneous disease modulated by a wide spectrum of factors, such as genetic, molecular, cellular, tissue, population, environmental and socioeconomic factors, which evolve with time. Proteomics plays a key role in saving many of people lives from deadliest disease of cancer by ad-

vancing the study of normal protein function and their conversion to cancerous proteins after post translational modifications and this advancement leads to development of personalized cancer therapies and medications. These findings like single cell proteomics, multi-omics approach and identification of cancer biomarkers highlights the value of proteogenomics in tailoring cancer therapies to individual patients, ultimately advancing the development of precision oncology. In conclusion, proteomics has emerged as a transformative approach for understanding cancer biology, identifying novel biomarkers, and advancing personalized medicine. By providing direct insights into protein expression, signaling pathways, and therapeutic responses, proteomics offers opportunities to improve both cancer diagnosis and treatment. Although significant challenges remain, continued technological innovation and interdisciplinary collaboration are expected to bring proteomics closer to routine clinical implementation, ultimately improving outcomes for cancer patients worldwide.

4. Recommendations

Future research should focus on biomarker validation, standardized proteomic workflows, integration with multi-omics approaches, improved bioinformatics, and broader clinical implementation to advance personalized cancer management.

Abbreviations

AI	Artificial Intelligence
BC	Breast Cancer
CPTAC	Clinical Proteomic Tumor Analysis Consortium
IARC	International Agency for Research on Cancer
PTM	Post-Translational Modification

Author Contributions

Muhammad Ahsan: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Resources, Visualization, Writing – original draft, Writing – review & editing

Conflicts of Interest

The author declares no conflicts of interest.

References

[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

[2] Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654

[3] Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology, 23(11), 2513–2520. https://doi.org/10.1200/JCO.2005.00.992

[4] Middleton, J. D., Stover, D. G., & Hai, T. (2018). Chemotherapy-exacerbated breast cancer metastasis: A paradox explained by dysregulated adaptive-response pathways. International Journal of Molecular Sciences, 19(11), 3333. https://doi.org/10.3390/ijms19113333

[5] Karagiannis, G. S., Pastoriza, J. M., Wang, Y., Harney, A. S., Entenberg, D., Pignatelli, J., Sharma, V. P., Xue, E. A., Cheng, E., D'Alfonso, T. M., et al. (2017). Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Science Translational Medicine, 9(397), eaan0026. https://doi.org/10.1126/scitranslmed.aan0026

[6] Ming, H., Li, B., Zhou, L., Goel, A., & Huang, C. (2021). Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications. Biochimica et Biophysica Acta Reviews on Cancer, 1875(2), 188519. https://doi.org/10.1016/j.bbcan.2021.188519

[7] Ren, Y., Zhou, X., Yang, J., Liu, X., Zhao, X., Wang, Q., Han, L., Song, X., Zhu, Z., Tian, W., et al. (2015). AC1MMYR2 impairs high-dose paclitaxel-induced tumor metastasis by targeting the miR-21/CDK5 axis. Cancer Letters, 362(2), 174–182. https://doi.org/10.1016/j.canlet.2015.03.038

[8] Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422(6928), 198–207. https://doi.org/10.1038/nature01511

[9] Veenstra, T. D. (2007). Proteomics and the discovery of cancer biomarkers. Clinical Chemistry, 53(12), 2006–2009. https://doi.org/10.1373/clinchem.2007.087536

[10] Califf, R. M. (2018). Biomarker definitions and their applications. Experimental Biology and Medicine, 243(3), 213–221. https://doi.org/10.1177/1535370217750088

[11] Mertins, P., Mani, D. R., Ruggles, K. V., et al. (2016). Proteogenomics connects somatic mutations to signalling in breast cancer. Nature, 534(7605), 55–62. https://doi.org/10.1038/nature18003

[12] Labib, M., & Kelley, S. O. (2020). Single-cell analysis targeting the proteome. Nature Reviews Chemistry, 4(3), 143–158. https://doi.org/10.1038/s41570-020-0162-7

[13] Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., & Nice, E. C. (2021). Proteomics, personalized medicine and cancer. Cancers, 13(10), 2337. https://doi.org/10.3390/cancers13102337

[14] Tan, Y. C., Low, T. Y., Lee, P. Y., & Lim, L. C. (2024). Single-cell proteomics by mass spectrometry: Advances and implications in cancer research. Proteomics, 24, e2300210. https://doi.org/10.1002/pmic.202300210

[15] Wenk, D., Zuo, C., Kislinger, T., Sepiashvili, L., et al. (2024). Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers. Clinical Proteomics, 21, 6.

[16] Li, X., et al. (2024). Proteomics mining of cancer hallmarks on a single-cell resolution. Mass Spectrometry Reviews. https://doi.org/10.1002/mas.21842